A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) received mixed analyst ratings with a general downward trend in price targets. The average 12-month price target is now $128.79, down 15.39% from the previous $152.22. Analysts' actions included maintaining, raising, and lowering ratings and price targets. Sarepta focuses on developing drugs for rare diseases using RNA-targeted technology and has shown a 44.1% revenue growth rate but faces challenges with market capitalization, ROE, ROA, and a high debt-to-equity ratio.
January 10, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sarepta Therapeutics has a mixed outlook from analysts, with a downward trend in price targets suggesting caution. Despite strong revenue growth, financial challenges such as a high debt-to-equity ratio may concern investors.
The mixed analyst ratings and lowered price targets indicate uncertainty, which could lead to a neutral short-term impact on SRPT's stock price. The strong revenue growth is positive, but financial challenges could offset investor sentiment.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100